Covance Boosts Phase I/IIa Capacity

Sunday, April 30, 2006 11:18 AM

The search for top quality phase I sites just got even harder as Covance, a leader in the hot early clinical development arena, entered into a definitive agreement to acquire eight early phase clinical development sites from Radiant Research, a site management organization that owns 30 sites, for $65 million. Covance is paying about 2.5 times revenue for the eight sites, which generate $25 million in annual revenue. Seattle-based Radiant Research will continue to operate its phase II through IV sites,but employees associated with the eight phase I sites will become Covance employees. Covance, one of the top global contract research organizations (CROs), has more than 7,300 employees worldwide.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs